NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lexicon Pharmaceuticals, Inc. LXRX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$49.8M
▲ 60.2% vs FY2024
EPS · FY25
$-0.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-39.7%
Net margin · FY25
-101.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 49.8M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 101 cents on every revenue dollar this year.
Per share
USD -0.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-39.7%
Return on equity, FY2025
ROE
Operating margin-98.2%
Net margin-101.1%
Return on assets-20.8%
Each USD of equity lost 40 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+16.3%
−9.1%
+16.7%
Returned to shareholders
+13.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.37B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 185.0M
total assets, end of FY2025
Total assetsUSD 185.0M
EquityUSD 107.5M
CashUSD 34.3M
Gross debtUSD 54.0M
Net debtUSD 19.7M
Current ratio4.88×
Net debt stands at 18% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.2
−0.2
−0.1
−0.1
−0.0
0.1
−0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.0
−0.2
−0.2
−0.1
−0.1
−0.0
0.1
−0.1
−0.1
−0.1
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
·
0.0
0.0
0.0
0.0
·
·
·
·
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−0.14
−0.63
−0.80
−0.62
−0.60
−0.53
1.16
−1.14
−1.17
−1.27
−0.05
−1.31
−1.42
−0.23
−0.34
−0.34
−0.57
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−39.7
−167.7
−168.5
−88.4
−65.0
−42.8
287.0
−576.0
−104.3
−58.0
−1.6
−44.2
−47.7
−39.1
−42.7
−41.2
·
Shares out B
0.37
0.36
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed